Alyftrek available in Scotland

Alyftrek (deutivacaftor/tezacaftor/vanzacaftor), is a new once-a-day triple combination modulator drug. It provides a treatment option for some people who are not eligible or able to take Kaftrio and an alternative for people who are already taking Kaftrio. 

Read our FAQs to find out more

Please speak to your CF team for further information about your own treatment options.

David Ramsden, Cystic Fibrosis Trust Chief Executive, said: Today marks an important step in access across the UK to the best available treatments for cystic fibrosis, and continues the progress from years of campaigning from the CF community. Cystic fibrosis continues to make lives too tough and too short, which is why it is important that everyone with the condition can benefit from the latest drugs.

“But, we must remember that these medicines don’t work for everyone and are not a cure, which is why we will continue funding vital research to work towards a future where everyone can benefit from a life unlimited by CF.”